Venture Capital

Latest Headlines

Latest Headlines

Evgen pitches downsized IPO to support trials of vegetable-inspired pipeline

Evgen Pharma has rebooted its IPO plans months after abandoning an attempt to raise £20 million ($30 million) on the London Stock Exchange. The aim now is to tap investors for £5 million, a sum that will support Phase II trials of Evgen's vegetable-inspired drug in breast cancer and stroke.

Cell Therapy mulls IPO as regenerative medicine boards EMA fast track

The European Medicines Agency has put Cell Therapy's Heartcel on its conditional approval pathway, raising the possibility that the allogeneic stem cell therapy could come to market in 2017. And with the drug now nearing the market, Cell Therapy has begun to sound out investors about an IPO.

Merck-partnered Euroscreen raises €16M to support IND filing

Euroscreen has topped up its bank balance to support the globalization of its clinical trial program. The €16 million ($18 million) round will allow the G-protein coupled receptor specialist to file an IND and advance ongoing Phase II trials of its lead candidate in women's health diseases.

Quartet closes an upsized A round with a novel approach to pain

Atlas Venture startup Quartet Medicine added $6.25 million to its Series A fundraise, closing the round at $23.25 million as it moves toward clinical trials with a newfangled way of treating chronic pain.

Elcelyx raises $40M to push its reinvented diabetes drug to Phase III

Elcelyx Therapeutics, developing a long-acting formulation of the old diabetes treatment metformin, closed a $40 million funding round to advance its lead therapy toward pivotal trials.

Neil Woodford gambles $25M on a rare genetic disease startup

Neil Woodford's Patient Capital Trust has blessed the British-American biotech hybrid AMO Pharma with a $25 million investment to help fund development of a small pipeline of therapies for rare genetic disorders.

Execs behind Imbruvica raise $75M for a new cancer project

Corvus Pharmaceuticals, led by some former Pharmacyclics executives, banked a $75 million B round to support its work on an oral treatment that uses the body's natural defenses to combat cancer.

Accelerator raises another $11.7M to fund its biotech bets

Accelerator, digging into the New York biotech scene, added another $11.7 million in new investments to its fourth fund, totaling $62.8 million earmarked for bets in life sciences.

Sofinnova leads a $30.6M round for Asceneuron's Alzheimer's R&D

Three years ago, after Merck Serono pulled the plug on its operations in Switzerland, a team of 8 neurodegeneration specialists used the shutdown as an opportunity to start their own biotech spinout, dubbed Asceneuron. And now they've gathered a substantial $30.6 million round to fund their drive into the clinic with a new drug candidate for Alzheimer's disease.

Kinase-focused Deciphera gets marquee backing for a big $75M venture round

A little more than a year after Deciphera CEO Mike Taylor set up an office for the biotech in the Boston area, the cancer drug developer has rounded up a whopping $75 million B round to make a clinical push for its top cancer drug candidates.